Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.
Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer.